Merrimack Pharmaceuticals Stock Income Statements

Merrimack Pharmaceuticals Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

Merrimack Pharmaceuticals Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2022-12-31	2021-12-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31
revenue	-445,000	-144,000	61,240,000	28,071,000	33,681,000	21,281,000	21,418,000	16,440,000	36,558,000	14,842,000	33,905,000	28,002,000	27,815,000	13,034,000	7,823,000	6,856,000	18,452,000	14,655,000	14,191,000	11,323,000	12,063,000	11,344,000	12,577,000	8,582,000	6,595,000	6,461,000	6,309,000	5,733,000	4,294,000	3,969,000
cost of revenue	445,000	0	3,319,000	1,010,000	1,872,000	711,000	46,000	0	0	0	10,635,000	0	33,795,000	30,324,000	30,055,000	0	42,465,000	36,989,000	34,564,000	30,885,000	28,758,000	31,651,000	27,529,000	23,913,000	31,187,000	18,001,000	16,418,000	15,079,000	13,366,000	13,415,000
gross profit	-890,000	-144,000	57,921,000	27,061,000	31,809,000	20,570,000	21,372,000	16,440,000	36,558,000	14,842,000	23,270,000	28,002,000	-5,980,000	-17,290,000	-22,232,000	6,856,000	-24,013,000	-22,334,000	-20,373,000	-19,562,000	-16,695,000	-20,307,000	-14,952,000	-15,331,000	-24,592,000	-11,540,000	-10,109,000	-9,346,000	-9,072,000	-9,446,000
operating expenses
research and development	0	0	54,961,000	32,078,000	40,996,000	32,882,000	44,740,000	37,763,000	42,806,000	35,679,000	30,744,000	43,632,000	33,795,000	30,324,000	30,055,000	37,630,000	42,465,000	36,989,000	34,564,000	30,885,000	28,758,000	31,651,000	365,000	0	0	0	0	0	0	0
sales, general and administrative
total operating expenses	607,000	473,000	79,167,000	50,126,000	61,676,000	50,677,000	64,075,000	54,719,000	55,121,000	44,868,000	39,021,000	51,727,000	41,716,000	36,548,000	36,065,000	42,780,000	47,560,000	41,921,000	38,719,000	4,312,000	3,610,000	3,728,000	3,215,000	3,306,000	4,832,000	3,101,000	2,826,000	3,123,000	2,979,000	2,453,000
operating income	-607,000	-473,000	-26,293,000	-23,874,000	-29,867,000	-30,107,000	-42,703,000	-38,279,000	-18,563,000	-30,026,000	-5,116,000	-23,725,000	-13,901,000	-23,514,000	-28,242,000	-35,924,000	-29,108,000	-27,266,000	-24,528,000	-23,874,000	-20,305,000	-24,035,000	-18,167,000	-18,637,000	-29,424,000	-14,641,000	-12,720,000	-12,506,000	-12,051,000	-11,899,000
net income	-492,000	-475,000	-32,449,000	-30,068,000	-50,750,000	-38,473,000	-47,826,000	-42,594,000	-22,778,000	-34,759,000	-9,696,000	-27,901,000	-18,109,000	-27,585,000	-33,059,000	-39,631,000	-30,082,000	-28,153,000	-24,768,000	-23,199,000	-20,026,000	-23,284,000	-18,116,000	-18,599,000	-29,051,000	-13,457,000	-10,095,000	-13,696,000	-13,249,000	-13,064,000

We provide you with 20 years income statements for Merrimack Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Merrimack Pharmaceuticals stock. Explore the full financial landscape of Merrimack Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Merrimack Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.